SAVBRAY

Class [005]
Pharmaceuticals, namely pharmaceutical preparations for the treatment of genetic disorders, namely X-linked adrenoleukodystrophy, Friedreich's ataxia; medicines for medical use, namely medicinal products for the treatment of neurodegenerative diseases, namely leukodystrophies, X-linked adrenoleukodystrophy, Friedreich's ataxia, Rett syndrome, Leigh's syndrome, Huntington's disease, Multiple System Atrophy (MSA); pharmaceutical preparations for the treatment of diseases of the central nervous system, namely leukodystrophies, X-linked adrenoleukodystrophy, Friedreich's ataxia, Rett syndrome, Multiple System Atrophy (MSA); pharmaceutical preparations for the prevention of diseases of the central and peripheral nervous system, namely leukodystrophies, X-linked adrenoleukodystrophy, Friedreich's ataxia, Rett's syndrome, Leigh's syndrome, Huntington's disease, Multiple System Atrophy (MSA), neuromuscular diseases being Amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Muscular dystrophy, Myasthenia gravis, Peripheral neuropathy, and Spinal muscular atrophy, cranial and spinal neuropathies, autonomic neuropathies, sensimotor neuropathies and plexopathies; pharmaceutical preparations for the treatment of diseases and disorders of the peripheral nervous system, namely X-linked adrenoleukodystrophy, Friedreich's ataxia, Rett's syndrome, Multiple System Atrophy (MSA), neuromuscular diseases being Amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Muscular dystrophy, Myasthenia gravis, Peripheral neuropathy, and Spinal muscular atrophy cranial and spinal neuropathies, autonomic neuropathies, sensimotor neuropathies and plexopathies.